Nephronophthisis (NPHP) is a renal ciliopathy affecting children and young adults. This review gives an update on the recent advances in the clinical features and related gene mutations of NPHP.
cardiac defects.
11 NPHP is also a major clinical finding in several syndromes, including Senior-Loken, Joubert, Meckel-Gruber, Cogan, and Sensenbrenner syndromes, and asphyxiating thoracic dystrophy (ATD, also known as Jeune syndrome). A summary of the main extra-renal manifestations associated with NPHP is described in Table 2 .
GENOTYPE-PHENOTYPE CORRELATION OF NPHP
To date, more than 25 different genes have been found to be associated with NPHP (Table 3) . 2, Mutations in the NPHP1 gene are the most common, being reported in approximately 20% of cases. Each of the remaining NPHP genes probably account for 1% or fewer of all cases of NPHP, and around two-thirds of cases remain genetically unknown. 41 Most nephrocystins are located in the transition zone, inversin compartment, or subunits of intraflagellar transport (IFT) complexes. 6 However, genome-wide homozygosity mapping identified pathogenic mutations in NPHP1L and NPHP2L of which the protein product localizes to mitochondria. 52 Currently, at least four distinct nephrocystin modules have been found: the NPHP1-4-8 module, NPHP2-3-9-ANKS6 module, NPHP5-6 module, and MKS module ( Fig. 1 ). These nephrocystin modules are related to different signalling pathways, including the Wnt pathway, Hedgehog pathway, DNA damage response (DDR) pathway, Hippo pathway, intracellular calcium signalling pathway, cAMP signalling pathway, and mTOR pathway.
NPHP shows genetic and phenotypic heterogeneity. Mutations in single ciliary genes are often associated with multiple phenotypes (Table 1 and Table 3 ). Single locus allelism is insufficient to explain the variability in phenotypic heterogeneity in NPHP. Digenic and triallelic inheritance may provide an explanation. Triallelic inheritance was first demonstrated for BBS. 53 To date, oligogenic inheritance has been noted in some patients with mutations in NPHP1, NPHP5, NPHP6, NPHP8, NPHP9, NPHP11, and TTC21B genes.
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APPROACH TO CLINICAL DIAGNOSIS OF NPHP
The diagnosis of NPHP is suggested by clinical features and confirmed by a positive genetic test (Fig. 2) . The role of renal biopsy in diagnosis is controversial. Renal biopsy should be limited to cases in which tissue diagnosis can be used to distinguish it from other differential diagnoses. Molecular genetic analysis is currently the only method available to diagnose NPHP and thus provide patients and families with an unequivocal diagnosis. Due to an increasing number of potentially causative monogenic genes and to advances in next-generation sequencing, whole-exome sequencing has mostly replaced targeted-sequencing panels in the diagnosis of NPHP. 57 Using this method, a causative single-gene mutation can be detected in up to 60% of cases depending on the composition of the cohort. However, the absence of mutation is not sufficient to exclude the diagnosis of NPHP. Most importantly, genetic testing should always be combined with thorough phenotyping and genetic counseling. Early onset autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease are often in the main differential diagnosis for patients with NPHP. Renal imaging may be useful in differential diagnosis. But genetic testing is required to make a definite diagnosis.
TREATMENT OF NPHP
There is no specific therapy for NPHP. Management is supportive, focusing on slowing the progression of CKD, controlling complications, and maintaining the promotion of growth. This disease does not recur after transplantation, so renal transplantation is the preferred renal replacement therapy.
Some potential therapeutic interventions have arisen from several lines of investigation into the pathogenesis of NPHP. Various personalized drugs include isosorbide dinitrate and tolvaptan (vasopressin V2 receptor antagonist), 58 dimethyl fumarate, 59 rapamycin (mTOR inhibitor), 60 roscovitine and its analog S-CR8 (cyclin-dependent kinases inhibitor), 61 purmorphamine (Shh signalling pathway agonist), 62 paclitaxel, 63 regulation of transcription factor Glis2/NPHP7
by SUMOylation, 64 and FR167653 (p38 MAPK pathway inhibitor). 65 Despite the many promising interventions that have arisen from preclinical studies, no clinical trials have yet been conducted in NPHP patients. Furthermore, large numbers of compounds which may be potential therapies are being screened in the zebrafish models of NPHP. 66 The lack of a clear-cut genotype-phenotype correlation remains a major challenge for physicians treating children with NPHP, even though the development of a single comprehensive histopathology and the discovery of specific disease genes and molecular mechanisms have significantly improved our understanding of NPHP. Only about 30% of NPHP patients have clear genetic mutations, suggesting that more NPHP genes have yet to be discovered. Novel genes will enable us to better understand the pathogenesis and relationship between cilia and cystic diseases. It is necessary to find new therapeutic strategies and develop alternative treatments other than conservative approaches and renal replacement therapy.
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